Hepatitis C is a risk factor for death after liver retransplantation
Open Access
- 21 March 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 11 (4) , 434-440
- https://doi.org/10.1002/lt.20342
Abstract
Retransplantation for liver allograft failure associated with hepatitis C virus (HCV) has been increasing due to nearly universal posttransplant HCV recurrence and has been demonstrated to be associated with poor outcomes. We report on the risk factors for death after retransplantation among liver recipients with HCV. A retrospective cohort of liver transplant recipients who underwent retransplantation between January 1997 and December 2002 was identified in the Scientific Registry of Transplant Recipients database. Cox regression was used to assess the relative effect of HCV diagnosis on mortality risk after retransplantation and was adjusted for multiple covariates. Of 1,718 liver retransplantations during the study period, 464 (27%) were associated with a diagnosis of HCV infection. Based on Cox regression, retransplant recipients with HCV had a 30% higher covariate-adjusted mortality risk than those without HCV diagnosis (hazard ratio [HR], 1.30; 95% confidence interval [CI], 1.10-1.54; P = 0.002). Other covariates associated with significant relative risk of death after retransplantation included older recipient age, presence in an intensive care unit (ICU), serum creatinine, and donor age. Additional regression analysis revealed that the increase in mortality risk associated with HCV was concentrated between 3 and 24 months postretransplantation, among patients age 18 to 39 at retransplant, and in patients retransplanted during the years 2000 to 2002. In conclusion, HCV liver recipients account for a considerable proportion of all retransplantations performed. Surprisingly, younger age predicted a higher mortality for recipients with HCV undergoing liver retransplantation. This may reflect a willingness to retransplant younger patients with an increased severity of illness or a more virulent HCV infection in this population. Although HCV was predictive of an increased risk of death, consideration of other characteristics of HCV patients, including donor and recipient age and need for preoperative ICU care may identify those at significantly higher risk. (Liver Transpl 2005;11:434–440.)Keywords
This publication has 32 references indexed in Scilit:
- Results of Retransplantation for Recurrent Hepatitis CHepatology, 2003
- Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosisLiver Transplantation, 2003
- Natural history of recurrent hepatitis CLiver Transplantation, 2002
- Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: Persistent elevation of serum transaminase levels versus necroinflammatory activityLiver Transplantation, 2000
- INTERFERON-?? FOR PROPHYLAXIS OF RECURRENT VIRAL HEPATITIS C IN LIVER TRANSPLANT RECIPIENTSTransplantation, 1998
- Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantationHepatology, 1997
- Severe recurrent cholestatic hepatitis C following orthotopic liver transplantationHepatology, 1996
- Long-Term Outcome of Hepatitis C Infection after Liver TransplantationNew England Journal of Medicine, 1996
- CLINICAL AND HISTOLOGIC PATTERNS OF EARLY GRAFT FAILURE DUE TO RECURRENT HEPATITIS C IN FOUR PATIENTS AFTER LIVER TRANSPLANTATIONTransplantation, 1996
- An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejectionHepatology, 1995